Advertisement

Immunmodulation: Neue Wege in der Tumortherapie

  • R. Dummer
  • J. C. Becker
  • A. A. Hartmann
  • C. Eilles
  • G. Burg
Conference paper
Part of the Fortschritte der operativen und onkologischen Dermatologie book series (OP.DERMATOLOGIE, volume 7)

Zusammenfassung

Die Immunmodulation zur Behandlung maligner Erkrankungen hat durch die experimentelle Immunologie neue Impulse erhalten. Rekombinante Zytokine ermöglichen es, Abwehrfunktionen des Immunsystems zu beeinflussen. Aufgrund verschiedener klinischer und experimenteller Beobachtungen erscheint der Einsatz der Immunmodulation gerade beim Melanom sinnvoll. Es wird ein adjuvantes Therapiekonzept, bestehend aus Interferon-alpha und Interleukin-2, sowie ein palliatives Behandlungsschema, bestehend aus Dacarbazin und Interleukin-2, vorgestellt. Untersuchungen mittels radioaktiv-markierter Lymphokinaktivierter Killerzellen können prognostische Bedeutung für spätere Immuntherapien haben. Trotz zahlreicher Probleme erscheinen immunmodulatorische Therapieansätze in der Onkologie vielversprechend.

Schlüsselwörter

Immunmodulation Immuntherapie adoptive Immuntherapie Melanom Interferon-alpha Interleukin-2 Lymphokin-aktivierte Killerzellen Tumor-infiltrierende Killerzellen. 

Summary

Recent findings in experimental immunology have opened the door to new approaches for immunomodulation in cancer therapy. Recombinant cytokines allow new approaches to augment immunofunctions. On the basis of various clinical and experimental observations, melanoma is a suitable target for immunomodulation. We present a treatment schedule for adjuvant melanoma therapy using interferon-alpha and interleukin 2 as well as combined chemo- and immunotherapy using dacarbazine and interleukin 2. Scintigraphy with radiolabeled lymphokine- activated killer cells might have prognostic relevance for immunotherapies. Despite a number of problems, immunomodulation is a promising approach in oncology.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Balch CM, Hersey P (1985) Heutiger Stand der adjuvanten Therapie. In: Balch CM, Milton GW, Shaw HM, Seng-jaw Soong (Hrsg). Hautmelanome. Diagnose, Therapie und weltweite Ergebnisse. Springer Verlag, Berlin Heidelberg New York, S 192–212Google Scholar
  2. 2.
    Becker JC, Dummer R, Burg G, Schmidt RE (1991) Shedding of ICAM-1 from human melanoma cell lines induced by interferon-gamma and tumors necrosis factor alpha: Functional consequences on cell mediated cytotoxicity. Immunol 147: 4398–4401Google Scholar
  3. 3.
    Berd D, Maguire HC, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an antologous tumor-cell vaccine: clinical and immunological results in 64 patients. J Clin Oncol 8: 1858–1867PubMedGoogle Scholar
  4. 4.
    Bergmann L, Weidmann E, Mitrou PS, Runne U, Keilholz U, Bartsch HH, Franks CR (1990) Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. Onkologie 13: 137–140PubMedCrossRefGoogle Scholar
  5. 5.
    Bystryn JC (1989) Immunosurveillance and melanoma. J Invest Dermatol 92: S318–320CrossRefGoogle Scholar
  6. 6.
    Chabner BA (1982) Nonclassical alkylating agents. In: Pharmacologic principles of cancer treatment. ( Chabner BA, ed) WB Saunders, Philadelphia, pp 340–362Google Scholar
  7. 7.
    Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES (1987) The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 129: 208–216PubMedGoogle Scholar
  8. 8.
    Dummer R, Welters H, Keilholz U, Tilgen W, Burg G (1990) Interleukin-2: Immunologischer Hintergrund und klinische Anwendung in der Tumortherapie. Hautarzt 41: 53–55PubMedGoogle Scholar
  9. 9.
    Dummer R, Becker JC, Kahlhammer U, Michaelis A, Ostmeier H, Tschammler A, Hartmann AA, Burg G (1991) Combined Chemo- and Immunotherapy using dacarbazine and continuous infusion of interleukin-2 in metastatic malignant melanoma. Eur J Dermatol 1: 201–205Google Scholar
  10. 10.
    Dummer R, Müller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G (1991) Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 57: 2300–2304CrossRefGoogle Scholar
  11. 11.
    Dummer R, Miller K, Eilles C, Burg G (1991) The skin: an Immunoreactive target organ during interleukin-2 administration. Dermatologica 183: 95–99PubMedCrossRefGoogle Scholar
  12. 12.
    Figlin RA, Itri LM (1988) Anti-interferon antibodies: A perspective. Semin Hematol 25: 9–15PubMedGoogle Scholar
  13. 13.
    Gambacorti-Passerini C, Rivoltini L, Radrizzani M, Supino R, Mariani M, Parmiani G (1988) Susceptibility of human and murine drug-resistent tumor cells to the lytic activity of rIL-2 activated lymphocytes ( LAK ). Cancer Metastasis Rev 7: 335–345PubMedCrossRefGoogle Scholar
  14. 14.
    Garbe C, Burg G, Drepper H, Rassner G (1989) Die Prognose des malignen Melanoms im klinischen Stadium I. Hautarzt 40: 378Google Scholar
  15. 16.
    Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosenberg SA (1989) In vivo distribution of adoptively transferred Indium-Ill-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81: 1709–1717PubMedCrossRefGoogle Scholar
  16. 17.
    Luger TA, Schwarz T (1991) Therapeutic use of cytokines in dermatology. J Am Acad Dermatol 24: 915–926PubMedCrossRefGoogle Scholar
  17. 18.
    Maeda K, Lafreniere R, Jerry LM (1991) Production and characterization of tumor infiltration lymphocyte clones derived from B16–F10 murine melanoma. J Invest Dermatol 97: 183–189PubMedCrossRefGoogle Scholar
  18. 19.
    Melder RJ, Whiteside TL, Vujanovic NL, Hiderodt JC, Herberman RB (1988) A new approach to generating antitumor effectors for adoptive immunotherapy using adherent lymphokine-activated killer cells. Cancer Res 48: 3461–3469PubMedGoogle Scholar
  19. 20.
    Nauts HC, Fowler GA, Bogatko FH (1953) A review of the influence of bacterial infection and of bacterial products ( Coley’s toxine) on malignant tumors in man. Acta Med Scand S 276: 1–103Google Scholar
  20. 21.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson CG, Carter C, Bock S, Schwarzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676–1680PubMedCrossRefGoogle Scholar
  21. 22.
    Rosenberg SA, Lotze MT, Yang JC, Lineham WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE (1989) Combination therapy with interleukin-2 and interferon alpha for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863–1874PubMedGoogle Scholar
  22. 23.
    Schäfer E, Dummer R, Eilles C, Martin M, Börner W, Burg G (1991) Imaging pattern of radiolabeled lymphokine-activated killer cells in malignant melanoma patients. Eur J Nucl Med 18: 106–110PubMedCrossRefGoogle Scholar
  23. 24.
    Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Schoenberger C, Longo DL (1988) Resistance to recombinant interferon-alpha2 a in hairy cell leucemia associated with neutralizing interferon antibodies. N Engl J Med 318: 1409–1413PubMedCrossRefGoogle Scholar
  24. 25.
    Swift RI, Danepure HJ, Osman S, Gaer J, Tsikos C, Peters AM, Lavender JP, Tebbut S, Habib NA, Wood CB (1991) Imaging of metastatic colorectal cancer with tumour-activated killer lymphocytes. Lancet 337: 1511–1512PubMedCrossRefGoogle Scholar
  25. 26.
    von Wussow P (1990) Interferontherapie bei ausgewählten soliden Tumoren. In: Interferone: präklinische und klinische Befunde. Niederle N und von Wussow P (Hrsg.) Springer, Berlin Heidelberg New York, S 234–245Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. Dummer
  • J. C. Becker
  • A. A. Hartmann
  • C. Eilles
  • G. Burg

There are no affiliations available

Personalised recommendations